Shark Tank Tales is reader supported and may receive a commission on qualified links. Learn More

EZC Pak: Immune Boost

Summary

SEASON 11 EPISODE 6

PITCH

echinacea, zinc, and vitamin C immune support pack

ENTREPRENEUR

Sarath Malepati

ASKED FOR

$125,000 for 5%

DEAL

$125,000 for 5% + $1 royalty per unit until $450,000 is repaid

SHARK

Kevin O’Leary

STATUS

IN BUSINESS

Company Background

What is EZC Pak?

EZC Pak is an immune support supplement designed for tapered use over five days. Because EZC Pak is technically a supplement, it is available over-the-counter in stores such as CVS and medical clinics throughout the U.S. The supplement contains echinacea, zinc, and vitamin C, all of which have shown some clinic use.

Who Owns EZC Pak?

EZC Pak was founded by Dr. Sarath Malepati. At 25, Dr. Malepati was the youngest member of the Georgetown University School of Medicine faculty. Today he is a California-based surgeon and physician who spends his time as the Medical Director and founder of the Los Angeles-based PPC Group Health Product team, while running the EZC Pak business.

Founder’s Story

Part of the problem is the over-prescribing of antibiotics, of which infections develop resistance to standard antibiotics. Over several years, Dr. Malepati came to understand that upper respiratory infections were not bacterial-based. So he developed EZC Pak to help the body boost its immune system.

Dr. Malepati was motivated partly because of the 29,000 people who die each year from C. diff colitis, an iatrogenic disease. This class of diseases originates from medical examination. Iatrogenic diseases are significantly reduced with proper hand hygiene.

The doctor’s research found that many doctors are pressured into prescribing antibiotics when they aren’t necessary. Dr. Malepati had a way to help reduce unneeded antibiotic use but did not have a national partner. His hope was that with help from Shark Tank, he could tap into a vast network of marketing experts that could him market his product nationally.

Read Comments (0)

Leave a Comment